Standard BioTools Inc
NASDAQ:LAB

  • LAST PRICE
    2.1150
  • TODAY'S CHANGE (%)
    0.0150 (0.7143%)
  • Bid / Lots
    2.1100/ 92
  • Ask / Lots
    2.1200/ 47
  • Open / Previous Close
    2.0800 / 2.1000
  • Day Range
    2.0600
    2.2300
  • 52 Week Range
    1.2100
    3.0400
  • Volume
    2,789,022

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 31, 2024

  • Oct 30, 2024

      Show headlines and story abstract

    • 4:45PM ET on Wednesday Oct 30, 2024 by MT Newswires
      Companies Mentioned: LAB
      04:45 PM EDT, 10/30/2024 (MT Newswires) -- ...

    • 4:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: LAB
      ITEMIZED RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA As Reported -------------------------------------------------- Three Months Ended Nine Months Ended -------------------------- ---------------------- September September September September 30, 2024 30, 2023 30, 2024 30, 2023 ------------ ------------ ---------- ---------- Net loss $(26,938) $(20,997) $(104,813) $ (54,880) Income tax expense (benefit) 118 50 301 614 Interest income, net (3,941) (340) (13,559) (656) Amortization of acquired intangible assets 716 2,800 3,533 8,400 Depreciation and amortization 3,431 1,186 9,375 2,874 Bargain purchase gain -- -- (25,213) -- Restructuring and related charges 2,341 1,998 12,374 5,415 Transaction and integration expenses 5,079 1,666 25,024 1,666 Stock-based compensation expense 5,921 3,386 24,262 9,648 Cost of sales adjustment -- -- (1,812) -- Gain/loss on disposal of property and equipment 30 -- 415 73 Other non-operating expense (957) 115 865 (292) Adjusted EBITDA (14,200) (10,136) (69,248) (27,138) Non-GAAP Pro Forma Combined -------------------------------------------------- Three Months Ended Nine Months Ended -------------------------- ---------------------- September September September September 30, 2024 30, 2023 30, 2024 30, 2023 ------------ ------------ ---------- ---------- Net loss $(26,938) $(41,204) $(134,607) $(109,000) Income tax expense (benefit) 118 528 301 1,096 Interest income, net (3,941) (6,447) (13,559) (17,604) Amortization of acquired intangible assets 716 3,516 3,533 10,549 Depreciation and amortization 3,431 2,870 9,375 7,924 Bargain purchase gain -- -- -- (25,213) Restructuring and related charges 2,341 1,998 12,374 6,515 Transaction and integration expenses 5,079 5,823 35,193 5,823 Stock-based compensation expense 5,921 4,928 17,416 21,151 Cost of sales adjustment -- -- -- (1,337) Gain/loss on disposal of property and equipment 30 -- 415 122 Other non-operating expense (957) (170) 658 (2,065) Adjusted EBITDA (14,200) (28,158) (68,901) (102,039)

    • 4:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: LAB

Peers Headlines